P53 expression in pretreatment specimen predicts response to neoadjuvant chemotherapy including anthracycline and taxane in patients with primary breast cancer

Tadahiko Shien, Takayuki Kinoshita, Kunihiko Seki, Miwa Yoshida, Takashi Hojo, Chikako Shimizu, Naruto Taira, Hiroyoshi Doihara, Sadako Akashi-Tanaka, Hitoshi Tsuda, Yasuhiro Fujiwara

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

While clinical and pathologic responses are important prognostic parameters, biological markers from core needle biopsy (CNB) are needed to predict neoadjuvant chemotherapy (NAC) response, to indi-vidualize treatment, and to achieve maximal efficacy. We retrospectively evaluated the cases of 183 patients with primary breast cancer who underwent surgery after NAC (anthracycline and taxane) at the National Cancer Center Hospital (NCCH). We analyzed EGFR, HER2, and p53 expression and common clinicopathological features from the CNB and surgical specimens of these patients. These biological markers were compared between sensitive patients (pathological complete response; pCR) and insensitive patients (clinical no change; cNC and clinical progressinve disease; cPD). In a com-parison between the 9 (5%) sensitive patients and 30 (16%) insensitive patients, overexpression of p53 but not overexpression of either HER2 or EGFR was associated with a good response to NAC. p53 (p - 0.045) and histological grade 3 (p - 0.011) were important and significant predictors of the response to NAC. The correspondence rates for histological type, histological grade 3, ER, PgR, HER2, p53, and EGFR in insensitive patients between CNB and surgical specimens were 70%, 73%, 67%, 70%, 80%, 93%, and 73%. The pathologic response was significantly associated with p53 expression and histological grade 3. The correspondence rate of p53 expression between CNB and surgical specimens was higher than that of other factors. We conclude that the level of p53 expression in the CNB was an effective and reliable predictor of treatment response to NAC

Original languageEnglish
Pages (from-to)165-170
Number of pages6
JournalActa Medica Okayama
Volume67
Issue number3
Publication statusPublished - 2013

Fingerprint

Chemotherapy
Biopsy
Anthracyclines
Large-Core Needle Biopsy
Needles
Breast Neoplasms
Drug Therapy
Biomarkers
Surgery
Cancer Care Facilities
taxane
Therapeutics

Keywords

  • Breast cancer
  • Neoadjuvant chemotherapy
  • Predictors

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

P53 expression in pretreatment specimen predicts response to neoadjuvant chemotherapy including anthracycline and taxane in patients with primary breast cancer. / Shien, Tadahiko; Kinoshita, Takayuki; Seki, Kunihiko; Yoshida, Miwa; Hojo, Takashi; Shimizu, Chikako; Taira, Naruto; Doihara, Hiroyoshi; Akashi-Tanaka, Sadako; Tsuda, Hitoshi; Fujiwara, Yasuhiro.

In: Acta Medica Okayama, Vol. 67, No. 3, 2013, p. 165-170.

Research output: Contribution to journalArticle

Shien, T, Kinoshita, T, Seki, K, Yoshida, M, Hojo, T, Shimizu, C, Taira, N, Doihara, H, Akashi-Tanaka, S, Tsuda, H & Fujiwara, Y 2013, 'P53 expression in pretreatment specimen predicts response to neoadjuvant chemotherapy including anthracycline and taxane in patients with primary breast cancer', Acta Medica Okayama, vol. 67, no. 3, pp. 165-170.
Shien, Tadahiko ; Kinoshita, Takayuki ; Seki, Kunihiko ; Yoshida, Miwa ; Hojo, Takashi ; Shimizu, Chikako ; Taira, Naruto ; Doihara, Hiroyoshi ; Akashi-Tanaka, Sadako ; Tsuda, Hitoshi ; Fujiwara, Yasuhiro. / P53 expression in pretreatment specimen predicts response to neoadjuvant chemotherapy including anthracycline and taxane in patients with primary breast cancer. In: Acta Medica Okayama. 2013 ; Vol. 67, No. 3. pp. 165-170.
@article{fe1184f692e6420c911894e35db9eb62,
title = "P53 expression in pretreatment specimen predicts response to neoadjuvant chemotherapy including anthracycline and taxane in patients with primary breast cancer",
abstract = "While clinical and pathologic responses are important prognostic parameters, biological markers from core needle biopsy (CNB) are needed to predict neoadjuvant chemotherapy (NAC) response, to indi-vidualize treatment, and to achieve maximal efficacy. We retrospectively evaluated the cases of 183 patients with primary breast cancer who underwent surgery after NAC (anthracycline and taxane) at the National Cancer Center Hospital (NCCH). We analyzed EGFR, HER2, and p53 expression and common clinicopathological features from the CNB and surgical specimens of these patients. These biological markers were compared between sensitive patients (pathological complete response; pCR) and insensitive patients (clinical no change; cNC and clinical progressinve disease; cPD). In a com-parison between the 9 (5{\%}) sensitive patients and 30 (16{\%}) insensitive patients, overexpression of p53 but not overexpression of either HER2 or EGFR was associated with a good response to NAC. p53 (p - 0.045) and histological grade 3 (p - 0.011) were important and significant predictors of the response to NAC. The correspondence rates for histological type, histological grade 3, ER, PgR, HER2, p53, and EGFR in insensitive patients between CNB and surgical specimens were 70{\%}, 73{\%}, 67{\%}, 70{\%}, 80{\%}, 93{\%}, and 73{\%}. The pathologic response was significantly associated with p53 expression and histological grade 3. The correspondence rate of p53 expression between CNB and surgical specimens was higher than that of other factors. We conclude that the level of p53 expression in the CNB was an effective and reliable predictor of treatment response to NAC",
keywords = "Breast cancer, Neoadjuvant chemotherapy, Predictors",
author = "Tadahiko Shien and Takayuki Kinoshita and Kunihiko Seki and Miwa Yoshida and Takashi Hojo and Chikako Shimizu and Naruto Taira and Hiroyoshi Doihara and Sadako Akashi-Tanaka and Hitoshi Tsuda and Yasuhiro Fujiwara",
year = "2013",
language = "English",
volume = "67",
pages = "165--170",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "3",

}

TY - JOUR

T1 - P53 expression in pretreatment specimen predicts response to neoadjuvant chemotherapy including anthracycline and taxane in patients with primary breast cancer

AU - Shien, Tadahiko

AU - Kinoshita, Takayuki

AU - Seki, Kunihiko

AU - Yoshida, Miwa

AU - Hojo, Takashi

AU - Shimizu, Chikako

AU - Taira, Naruto

AU - Doihara, Hiroyoshi

AU - Akashi-Tanaka, Sadako

AU - Tsuda, Hitoshi

AU - Fujiwara, Yasuhiro

PY - 2013

Y1 - 2013

N2 - While clinical and pathologic responses are important prognostic parameters, biological markers from core needle biopsy (CNB) are needed to predict neoadjuvant chemotherapy (NAC) response, to indi-vidualize treatment, and to achieve maximal efficacy. We retrospectively evaluated the cases of 183 patients with primary breast cancer who underwent surgery after NAC (anthracycline and taxane) at the National Cancer Center Hospital (NCCH). We analyzed EGFR, HER2, and p53 expression and common clinicopathological features from the CNB and surgical specimens of these patients. These biological markers were compared between sensitive patients (pathological complete response; pCR) and insensitive patients (clinical no change; cNC and clinical progressinve disease; cPD). In a com-parison between the 9 (5%) sensitive patients and 30 (16%) insensitive patients, overexpression of p53 but not overexpression of either HER2 or EGFR was associated with a good response to NAC. p53 (p - 0.045) and histological grade 3 (p - 0.011) were important and significant predictors of the response to NAC. The correspondence rates for histological type, histological grade 3, ER, PgR, HER2, p53, and EGFR in insensitive patients between CNB and surgical specimens were 70%, 73%, 67%, 70%, 80%, 93%, and 73%. The pathologic response was significantly associated with p53 expression and histological grade 3. The correspondence rate of p53 expression between CNB and surgical specimens was higher than that of other factors. We conclude that the level of p53 expression in the CNB was an effective and reliable predictor of treatment response to NAC

AB - While clinical and pathologic responses are important prognostic parameters, biological markers from core needle biopsy (CNB) are needed to predict neoadjuvant chemotherapy (NAC) response, to indi-vidualize treatment, and to achieve maximal efficacy. We retrospectively evaluated the cases of 183 patients with primary breast cancer who underwent surgery after NAC (anthracycline and taxane) at the National Cancer Center Hospital (NCCH). We analyzed EGFR, HER2, and p53 expression and common clinicopathological features from the CNB and surgical specimens of these patients. These biological markers were compared between sensitive patients (pathological complete response; pCR) and insensitive patients (clinical no change; cNC and clinical progressinve disease; cPD). In a com-parison between the 9 (5%) sensitive patients and 30 (16%) insensitive patients, overexpression of p53 but not overexpression of either HER2 or EGFR was associated with a good response to NAC. p53 (p - 0.045) and histological grade 3 (p - 0.011) were important and significant predictors of the response to NAC. The correspondence rates for histological type, histological grade 3, ER, PgR, HER2, p53, and EGFR in insensitive patients between CNB and surgical specimens were 70%, 73%, 67%, 70%, 80%, 93%, and 73%. The pathologic response was significantly associated with p53 expression and histological grade 3. The correspondence rate of p53 expression between CNB and surgical specimens was higher than that of other factors. We conclude that the level of p53 expression in the CNB was an effective and reliable predictor of treatment response to NAC

KW - Breast cancer

KW - Neoadjuvant chemotherapy

KW - Predictors

UR - http://www.scopus.com/inward/record.url?scp=84883646709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883646709&partnerID=8YFLogxK

M3 - Article

C2 - 23804139

AN - SCOPUS:84883646709

VL - 67

SP - 165

EP - 170

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 3

ER -